Rezolute (NASDAQ:RZLT) Stock Rating Reaffirmed by HC Wainwright

Rezolute (NASDAQ:RZLT)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $14.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 169.23% from the stock’s current price.

A number of other research analysts also recently commented on the company. Maxim Group increased their price objective on Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 6th. BTIG Research assumed coverage on shares of Rezolute in a report on Wednesday, July 17th. They set a “buy” rating and a $13.00 price objective on the stock. Guggenheim initiated coverage on shares of Rezolute in a research report on Tuesday, August 27th. They set a “buy” rating and a $11.00 price objective for the company. Finally, Craig Hallum started coverage on shares of Rezolute in a research report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 target price on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $10.75.

Rezolute Trading Down 2.1 %

Shares of NASDAQ RZLT opened at $5.20 on Monday. The business’s fifty day simple moving average is $4.49 and its 200-day simple moving average is $3.56. The stock has a market cap of $287.87 million, a P/E ratio of -4.56 and a beta of 1.18. Rezolute has a 12-month low of $0.72 and a 12-month high of $6.10.

Insider Transactions at Rezolute

In other Rezolute news, CFO Daron Evans bought 40,000 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were acquired at an average cost of $4.04 per share, with a total value of $161,600.00. Following the acquisition, the chief financial officer now directly owns 40,000 shares of the company’s stock, valued at approximately $161,600. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have acquired 49,115 shares of company stock worth $198,395. Insiders own 20.80% of the company’s stock.

Hedge Funds Weigh In On Rezolute

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in Rezolute during the 1st quarter worth $37,000. Jeppson Wealth Management LLC acquired a new stake in Rezolute in the second quarter valued at about $45,000. XTX Topco Ltd boosted its holdings in Rezolute by 205.8% in the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock valued at $145,000 after purchasing an additional 22,660 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Rezolute during the 1st quarter worth approximately $229,000. Finally, Cubist Systematic Strategies LLC raised its stake in shares of Rezolute by 366.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock worth $233,000 after buying an additional 42,597 shares in the last quarter. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.